id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1975-N-0336-0072,FDA,FDA-1975-N-0336,"Request for Extention from Concordia Pharmaceuticals, Inc. (Buchanan Ingersoll Rooney PC)",Other,Request for Extension,2015-05-14T04:00:00Z,2015,5,2015-05-14T04:00:00Z,,2015-05-14T19:44:56Z,,0,0,0900006481ae101d
FDA-1975-N-0336-0073,FDA,FDA-1975-N-0336,Response Letter from FDA CDER to Buchanan Ingersoll and Rooney PC,Other,Letter(s),2015-05-14T04:00:00Z,2015,5,2015-05-14T04:00:00Z,,2015-05-14T19:38:54Z,,0,0,0900006481ae101e
FDA-1975-N-0336-0071,FDA,FDA-1975-N-0336,"Letter from FDA CDER to Concordia Pharmaceuticals, Inc.",Other,Letter(s),2015-04-09T04:00:00Z,2015,4,2015-04-09T04:00:00Z,,2015-04-09T16:59:46Z,,0,0,0900006481a9826f